• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    Sponsored Content
    USP
    • Opinion
    • Sponsored by USP

    Opinion: Readying African vaccine manufacturers for the next pandemic

    As the urgency around the COVID-19 pandemic fades, three essential actions are needed to ensure vaccine manufacturing in Africa moves forward to help ready the continent for future pandemics.

    By Laura Martin, Evans Sagwa // 30 November 2022
    Three essential actions are needed to ensure vaccine manufacturing in Africa moves forward to help ready the continent for future pandemics. Photo by: Istock.com / Smederevac

    As the urgency and catastrophic impacts of the COVID-19 pandemic start to fade from the headlines, the movement to expand vaccine manufacturing in Africa has approached a critical moment. Expanding vaccines manufacturing on the continent emerged as a critical response to the delays that Africa faced in accessing COVID-19 vaccines. As a result, African stakeholders set out bold milestones of producing 10% of vaccines locally by 2025 and a long-term goal of producing 60% by 2040. But for these goals to be met, momentum and support cannot simply be maintained but needs to be drastically scaled up.

    Pivoting to greater local production

    As multiple efforts to expand vaccine manufacturing in Africa move forward, tipping the scales toward more sustainable vaccine production on the continent requires a rethink of biopharmaceutical manufacturing within well-established global health and investment frameworks and approaches.

    Across the supply chain, key actions are needed to drive sustainable vaccine manufacturing forward in Africa, bring vaccines closer to patients, and promote equitable access. The following are three priority actions that can help ensure current efforts are sustainable in the long term.

    1. De-risk investments in vaccine manufacturing

    The Pro read:

    De-risking health through blended finance 

    Agencies, financial institutions, and private firms are using blended finance to prove that health care companies are bankable.

    Investments in vaccine manufacturing are inherently risky. De-risking investments to the extent possible is essential to mobilize resources from development banks, private equity investors, and other sources of capital required to make the sizable investments in expanding vaccine production.

    The recent evaluation of the Access to COVID-19 Tools Accelerator, or ACT-A — the global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines — recommended the establishment of an Advanced Commitment Facility that could help fund early research and development projects and facilitate purchasing commitments starting on “day zero” of the next pandemic. This type of capital will be essential for future pandemic responses. However, advanced market commitments need to be adopted more broadly outside of pandemic-specific responses. Even for countries that were able to make advanced purchases, a lack of manufacturing capacity was a major challenge during the rollout of COVID-19 vaccines.

    Additional mechanisms for advanced market commitments as well as enabling trade and tax policies must be put in place during nonpandemic times to sustain and grow the manufacturing base. Without these supports, it is unlikely the sector will advance enough to have sufficient capacity to leverage during a future pandemic. Firm and transparent commitments from African governments, global and local procurement agencies, and donors will be essential in helping to shape sustainable markets that enable the sector to grow.

    2. Integrate manufacturing into pandemic preparedness efforts

    The ACT-A evaluators and many other stakeholders have flagged the importance of strengthening “regional manufacturing and health systems” as essential for future pandemic responses and pointed to the recently launched Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response, now known as The Pandemic Fund, as a key mechanism for doing so. However, expanding regional manufacturing in Africa is not included in the fund’s current thematic priorities.

    Strengthening and expanding manufacturing capacity should be part and parcel of health systems strengthening efforts and pandemic responses. Specific funding mechanisms, such as The Pandemic Fund, that aim to better equip health systems to respond to future pandemics must consider and invest in the development of sustainable regional biopharmaceutical manufacturing as part of these efforts.

    3. Prioritize development of the enabling ecosystem

    For vaccine manufacturing in Africa to be ready to respond to future pandemics and support routine vaccination during nonpandemic times, the focus must not be solely on supporting manufacturers themselves, but also on the enabling ecosystem required for the sector to succeed. One critical aspect is strengthening regulatory systems on the continent.

    Increased investments in national and regional regulatory bodies as well as targeted support to operationalize the African Medicines Agency are essential and will help to foster assurance of the quality of vaccines produced and protect populations from poor-quality vaccines.

    A key enabler also includes scaling up and maximizing continental-wide coordination mechanisms such as the Partnership for African Vaccine Manufacturing. Improved collaboration, information sharing, and a shared strategic vision not only help to make investments in vaccine manufacturing less risky, but can also assure that capacity built in one country or region complements rather than duplicates capacity in another region. This type of partnership and collaboration will require unprecedented levels of coordination between technical experts, politicians, and private-sector manufacturers and investors but will serve to foster sustainability of manufacturing across Africa.

    Additionally, expanding research and development capabilities and strengthening the pharmaceutical workforce are critical to building a sustainable vaccine manufacturing ecosystem and must not be overlooked. National governments, working with technical partners and the World Health Organization, should expand and incentivize academic as well as on-the-job training programs while leaning on resource training hubs such as WHO’s messenger RNA hub, the African Pharmaceutical Technology Institute, and others to develop and retain technical skills and capacity.

    The case for expanding vaccine manufacturing in Africa remains clear. But only through enhanced partnership, collaboration, and investment will we see the sector thriving in 2040.

    Read more:

    ► The African Medicines Agency was ratified: What's next? (Pro)

    ► Rwanda chosen to host the African Medicines Agency

    • Global Health
    • Innovation & ICT
    • Infrastructure
    • Trade & Policy
    • Private Sector
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
    The views in this opinion piece do not necessarily reflect Devex's editorial views.

    About the authors

    • Laura Martin

      Laura Martin

      Laura Martin is a vaccinologist and public health leader with more than 20 years of experience in the end-to-end development of vaccines for poverty related disease, working across industry, government, academia, and global health. As Vaccines Program Director at the United States Pharmacopeial Convention, Dr. Martin provides technical and programmatic leadership to the organization’s global health programs that work to expand equitable access to quality-assured vaccines in low- and middle-income countries.
    • Evans Sagwa

      Evans Sagwa

      Evans Sagwa is a pharmaceutical management expert and public health leader with more than 20 years of experience in strengthening health systems and supply chains in low- and middle-income countries. Sagwa has specific expertise in pharmaceutical policy and regulation, product safety, and quality assurance systems. He currently leads the USAID-funded Promoting the Quality of Medicines Plus program in Eastern and Southern Africa and is based in Nairobi, Kenya.

    Search for articles

    Related Stories

    Global healthHow Asia-Pacific can boost vaccine access in the next pandemic

    How Asia-Pacific can boost vaccine access in the next pandemic

    Global HealthAfrica’s vaccine manufacturing ambitions get a boost with new partnerships

    Africa’s vaccine manufacturing ambitions get a boost with new partnerships

    Pandemic preparednessOpinion: Failing to finalize a pandemic agreement is not an option

    Opinion: Failing to finalize a pandemic agreement is not an option

    Global healthOpinion: Trump aid shock underscores need for more made-in-Africa medicine

    Opinion: Trump aid shock underscores need for more made-in-Africa medicine

    Most Read

    • 1
      How to use law to strengthen public health advocacy
    • 2
      Closing the loop: Transforming waste into valuable resources
    • 3
      House cuts US global education funding 20%, spares multilateral partners
    • 4
      Lasting nutrition and food security needs new funding — and new systems
    • 5
      Opinion: The pursuit of remission — from possibility to priority
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement